在试验中评估治疗时考虑影响预后的竞争性治疗的重要性:以血液透析试验中的肾移植为例
该研究利用ESHOL(n=902)和CONTRAST(n=714)两项试验的个体患者数据,比较五种方法估计血液透析滤过(HDF)与血液透析(HD)对全因死亡率的影响,发现两试验未经调整的意向治疗分析结果不同(HR 0.95 vs 0.76),而将肾移植作为时变协变量并校正移植-结局混杂因素后,HR变得更相似(0.89 vs 0.80)。结论认为两试验估计的治疗效果差异在很大程度上归因于是否考虑肾移植的方法学差异。
要点
- 未调整的意向治疗分析中,CONTRAST试验HDF vs HD的HR为0.95(95%CI 0.75-1.20),ESHOL试验为0.76(95%CI 0.59-0.97)。
- 将肾移植作为时变协变量并校正移植-结局混杂因素后,CONTRAST的HR为0.89(95%CI 0.69-1.13),ESHOL为0.80(95%CI 0.62-1.02)。
- 两透析试验估计的治疗效果差异在很大程度上归因于是否考虑肾移植的方法学差异。
核心结论
- 两项透析试验之间估计的治疗效果差异在很大程度上归因于最终分析中考虑肾移植的方法学差异。
- 结果说明在参与者可能接受额外治疗的随机对照试验中估计治疗效果时,必须仔细考虑所关注的疗效。
研究设计与样本
- 利用ESHOL试验(n=902)和CONTRAST试验(n=714)的个体患者数据,比较五种估计HDF vs HD对全因死亡率效果的方法。
- 五种方法为:意向治疗分析(ITT,不考虑肾移植)、符合方案排除(PP excl,排除接受移植的患者)、符合方案截尾(PP cens,在移植时截尾)、移植校正分析(TA)及扩展的TA分析(TA ext,额外校正与接受移植风险和结局风险均相关的变量)。
- 应用Cox比例风险模型。
主要发现
- 未调整的ITT分析中,CONTRAST试验HDF vs HD的HR为0.95(95%CI 0.75-1.20),ESHOL试验为0.76(95%CI 0.59-0.97),风险降低分别为5%和24%。
- 其他未调整分析方法(PP cens、PP excl、TA)中两试验也观察到类似差异。
- 将移植作为时变协变量并纳入移植-结局混杂因素后,HDF vs HD的HR在CONTRAST为0.89(95%CI 0.69-1.13),在ESHOL为0.80(95%CI 0.62-1.02)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: During the follow-up in a randomized controlled trial (RCT), participants may receive additional (non-randomly allocated) treatment that affects the outcome. Typically such additional treatment is not taken into account in evaluation of the results. Two pivotal trials of the effects of hemodiafiltration (HDF) versus hemodialysis (HD) on mortality in patients with end-stage renal disease reported differing results. We set out to evaluate to what extent methods to take other treatments (i.e. renal transplantation) into account may explain the difference in findings between RCTs. This is illustrated using a clinical example of two RCTs estimating the effect of HDF versus HD on mortality. METHODS: Using individual patient data from the Estudio de Supervivencia de Hemodiafiltración On-Line (ESHOL; n = 902) and The Dutch CONvective TRAnsport STudy (CONTRAST; n = 714) trials, five methods for estimating the effect of HDF versus HD on all-cause mortality were compared: intention-to-treat (ITT) analysis (i.e. not taking renal transplantation into account), per protocol exclusion (PP excl ; exclusion of patients who receive transplantation), PP cens (censoring patients at the time of transplantation), transplantation-adjusted (TA) analysis and an extension of the TA analysis (TA ext ) with additional adjustment for variables related to both the risk of receiving a transplant and the risk of an outcome (transplantation-outcome confounders). Cox proportional hazards models were applied. RESULTS: Unadjusted ITT analysis of all-cause mortality led to differing results between CONTRAST and ESHOL: hazard ratio (HR) 0.95 (95% CI 0.75-1.20) and HR 0.76 (95% CI 0.59-0.97), respectively; difference between 5 and 24% risk reductions. Similar differences between the two trials were observed for the other unadjusted analytical methods (PP cens, PP excl , TA) The HRs of HDF versus HD treatment became more similar after adding transplantation as a time-varying covariate and including transplantation-outcome confounders: HR 0.89 (95% CI 0.69-1.13) in CONTRAST and HR 0.80 (95% CI 0.62-1.02) in ESHOL. CONCLUSIONS: The apparent differences in estimated treatment effects between two dialysis trials were to a large extent attributable to differences in applied methodology for taking renal transplantation into account in their final analyses. Our results exemplify the necessity of careful consideration of the treatment effect of interest when estimating the therapeutic effect in RCTs in which participants may receive additional treatments.
引用
- Hazelbag CM, Peters SAE, Blankestijn PJ, et al. The importance of considering competing treatment affecting prognosis in the evaluation of therapy in trials: the example of renal transplantation in hemodialysis trials. Nephrol Dial Transplant. 2017. PMID: 28339826. doi:10.1093/ndt/gfw458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。